+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Developmental and Epileptic Encephalopathies (DEE) - Market Insights, Epidemiology and Market Forecast - 2028

  • ID: 4985364
  • Report
  • February 2020
  • Region: Global
  • 299 Pages
  • DelveInsight

FEATURED COMPANIES

  • Biocodex
  • Eisai Pharmaceuticals
  • Greenwich Biosciences
  • Lundbeck
  • PTC Therapeutics
  • Takeda/Ovid

The ‘Developmental and Epileptic Encephalopathies (DEE)- Market Insights, Epidemiology and Market Forecast - 2028’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Developmental and Epileptic Encephalopathies (DEE) in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, the current and forecasted market size of Developmental and Epileptic Encephalopathies (DEE) from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2028

Developmental and Epileptic Encephalopathies (DEE) - Disease Understanding and Treatment Algorithm

Developmental and Epileptic Encephalopathies (DEE) consists of several types of severe brain disorders in which the epileptic electrical discharges may add to progressive psychomotor dysfunction. They are a group of nosologies that are related to an early age and manifest with electroencephalography (EEG) paroxysmal activity that is often aggressive, seizures that are commonly multi-form and intractable, cognitive, behavioral and neurological deficits that may be relentless and sometimes lead to early death. Cognitive deficits and behavioral disturbances are presumed to be the main and sometimes the first and unique manifestation of electrographic epileptic discharges in epileptic encephalopathy. There are various sub syndromes in Epileptic encephalopathies namely West syndrome, Dravet syndrome, Ohtahara syndrome, Lennox-gastaut, Landau-Kleffner syndrome, Epilepsy with Continuous Spike-and -Waves during Slow-Wave Sleep, Myoclonic Status in Non-Progressive Encephalopathies, Atypical Benign Partial Epilepsy of Childhood, Hypothalamic (Gelastic) Epilepsy.

The Developmental and Epileptic Encephalopathies market report gives a thorough understanding of the various Developmental and Epileptic Encephalopathies by including details such as disease introduction, causes, pathophysiology, clinical manifestations, diagnosis, differential diagnosis, and biomarkers. It also provides treatment algorithms and treatment guidelines for Developmental and Epileptic Encephalopathies in the US, Europe, and Japan.

Developmental and Epileptic Encephalopathies (DEE) Epidemiology

Infantile epileptic encephalopathies are defined by frequent or severe seizures, or sub-continuous paroxysmal interictal activity contributing to a progressive disturbance of cerebral function. These serious syndromes presenting during the first 12 months of life can be divided into several categories of encephalopathies. The incidence of such cases is highest in young children and older adults with children often having the most severe types of epilepsies. Approximately 40% of seizures occurring during the first three years of life are due to an epileptic encephalopathy (EE). As per the National Organization of Rare Disorders, Epileptic Encephalopathy is a rare genetic disorder that affects both males and females equally. So far s of about 50 patients have been published in various databases/publications.

As per the Dravet Syndrome Organization, Dravet syndrome is twice as common as previously recognized, affecting 1:15,700 infants, 80% of whom have an SCN1A mutation. A large number of children are not receiving an early diagnosis, which could have a dramatic impact on long-term development and quality of life.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology scenario of Developmental and Epileptic Encephalopathies in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and the United Kingdom) and

Japan from 2017-2028 for the following aspects:

  • Diagnosed Prevalence of Developmental and Epileptic Encephalopathy in the United States
  • Diagnosed Prevalence of Early Myoclonic Encephalopathy in the United States
  • Diagnosed Prevalence of Epileptic Encephalopathy with continuous spike and wave during sleep in the United States
  • Diagnosed Prevalence of Ohtahara Syndrome in the United States
  • Diagnosed Prevalence of West Syndrome in the United States
  • Diagnosed Prevalence of Landau-Kleffner Syndrome in the United States
  • Diagnosed Prevalence of Lennox-Gastaut Syndrome in the United States
  • Diagnosed Prevalence of Dravet Syndrome in the United States
  • Diagnosed Prevalence of Doose Syndrome in the United States

As per the study conducted in the Louisiana State University titled “Lennox-Gastaut Syndrome” by Amrutkar et al. stated that LGS (LGS) accounts for approximately 2-5% of all childhood epilepsies, but is responsible for roughly 10% of epilepsy cases occurring before the age of 5 years. The overall incidence of LGS is estimated at 0.1-0.28 per 100,000 population and specifically, in children the incidence is estimated at 2 per 100,000. In context, the overall prevalence, is about 26 per 100,000 people, which is more common in males than in females.

Krueger et al. in the study “Incidence of Dravet Syndrome in a US Population” stated that there were 125,547 births in the study population out of which 730 infants had two or more seizure visits before the age of one year. Eight infants met four of the five clinical criteria for Dravet Syndrome, equivalent to an incidence of 1 per 15,700 births. Six of the eight patients were found to have de novo mutations that were predicted to be pathogenic, equivalent to an incidence of 1 per 20,900.

This segment of the Developmental and Epileptic Encephalopathies report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

To meet the increasing demand for the treatment of Developmental and epileptic encephalopathies, companies have shifted their focus towards the development of targeted therapies. Expected launch of potential therapies may increase the market size in the coming years, assisted by an increase in the prevalent population of Developmental and Epileptic Encephalopathies & awareness of the disease. The overall dynamics of Developmental and Epileptic Encephalopathies market is anticipated to change in the coming years owing to the expected launch of emerging therapies of the major key players such as Eisai Pharmaceuticals, Zogenix, Takeda/Ovid and Zynerba Pharma will significantly increase the market during the forecast period (2019-2028).

Developmental and Epileptic Encephalopathies (DEE) Market Outlook

Epileptic encephalopathies are an epileptic condition characterized by epileptiform abnormalities associated with progressive cerebral dysfunction. Out of the syndromes of epileptic encephalopathies, infants are majorly affected with and LGS and DS. The three main forms of treatment of LGS and DS are anti-epileptic drugs (AEDs), dietary therapy (typically the ketogenic diet) or device/surgery (VNS therapy or corpus callosotomy). Valproate (Valproic acid) is one of the most useful initial medication of choice to control absence seizures, tonic-clonic seizures (grand mal), complex partial seizures, juvenile myoclonic epilepsy, and the seizures associated with LGS. Valproate is considered as the first line of therapy for LGS as it is effective against a wide spectrum of seizures, the drug is administered as a monotherapy, and if ineffective another drug such as lamotrigine, topiramate, rufinamide or clobazam may be added. It also has significant side effects ranging from tremor to reduction in platelet count and function as well as hyperammonemia.

Several drugs have been approved by the US Food and Drug Administration (FDA) for the treatment of LGS and DS, including different classes such as Sodium Channel Modulators, Gamma-Aminobutyric Acid (GABA) Receptor Modulator, Calcium Channel Blockers, Receptor Blockers and few in the other categories. Several AEDs consist of Epidiolex, Topamax, Banzel, Lamictal, Felbatol, Onfi, Klonopin, Diacomit while Sabril has been approved for the treatment of infantile spasms (a rare disease) and complex partial seizures.

This segment gives a thorough detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to the publisher, the market of Developmental and Epileptic Encephalopathies in 7MM is expected to change from 2019-2028.

Developmental and Epileptic Encephalopathies (DEE) Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Expected launch of therapies for Developmental and Epileptic Encephalopathies (DEE) such as Eisai Pharmaceuticals (Fycompa; Perampanel), Zogenix (Fintepla; ZX008), Takeda/Ovid (Soticlestat; TAK-935/OV935), and Zynerba Pharma (Zygel; ZYN002) and other targeted therapies in the forecast period [2019-2028] will also create a positive impact on the Developmental and Epileptic Encephalopathies (DEE) market.

Developmental and Epileptic Encephalopathies (DEE) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Developmental and Epileptic Encephalopathies (DEE) Report Key Strengths

  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition

Developmental and Epileptic Encephalopathies (DEE) Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits

  • This report will help to develop Business Strategies by understanding the trends shaping and driving Developmental and Epileptic Encephalopathies (DEE)market
  • Organize sales and marketing efforts by identifying the best opportunities for Developmental and Epileptic Encephalopathies (DEE)market
  • To understand the future market competition in the Developmental and Epileptic Encephalopathies (DEE) market.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Biocodex
  • Eisai Pharmaceuticals
  • Greenwich Biosciences
  • Lundbeck
  • PTC Therapeutics
  • Takeda/Ovid

1. Key Insights

2. Developmental and Epileptic Encephalopathies Market Overview at a Glance
2.1. Market Share (%) Distribution of Developmental and Epileptic Encephalopathies in 2017
2.2. Market Share (%) Distribution of Developmental and Epileptic Encephalopathies in 2028

3. Disease Background and Overview: Developmental and Epileptic Encephalopathies
3.1. West Syndrome
3.1.1. Clinical Manifestations
3.1.2. Etiology
3.1.3. Pathophysiology
3.1.4. Diagnosis
3.1.5. Differential Diagnosis
3.2. Dravet Syndrome
3.2.1. First Period of Mainly Febrile Convulsions
3.2.2. Second Relentlessly Aggressive Period
3.2.3. Third Static Period of Regression
3.2.4. Etiology
3.2.5. Diagnosis
3.2.6. Differential Diagnosis
3.3. Lennox-Gastaut Syndrome
3.3.1. Etiology
3.3.2. Pathophysiology
3.3.3. Diagnosis
3.3.4. Differential Diagnosis
3.4. Landau-Kleffner Syndrome (LKS)(Acquired Epileptic Aphasia)
3.4.1. Etiology
3.4.2. Pathophysiology
3.4.3. Diagnosis
3.4.4. Differential Diagnosis
3.5. Epilepsy with Continuous Spike-and -Waves during Slow-Wave Sleep
3.5.1. Etiology
3.5.2. Pathophysiology
3.5.3. Diagnostic Procedures
3.5.4. Differential Diagnosis
3.6. Myoclonic Status in Non-Progressive Encephalopathies
3.6.1. Etiology
3.6.2. Pathophysiology
3.6.3. Diagnosis
3.6.4. Differential Diagnosis
3.7. Atypical Benign Partial Epilepsy of Childhood
3.7.1. Diagnosis
3.7.2. Differential Diagnosis
3.8. Hypothalamic (Gelastic) Epilepsy
3.8.1. Etiology
3.8.2. Pathophysiology
3.8.3. Diagnosis
3.8.4. Differential Diagnosis
3.9. Indicators of DEES
3.9.1. Age of onset
3.9.2. Etiology
3.9.3. Epilepsy duration
3.9.4. Seizure characteristics
3.10. Biomarkers of epileptic encephalopathies
3.10.1. Neuroinflammation and Oxidative Stress
3.10.2. MicroRNA as the Novel Diagnostic Tools for Epilepsy
3.10.3. The Role of the Complement System in Epilepsy
3.10.4. Role of Cytokines in Epileptogenesis
3.10.5. Proteins and Amino Acids Role in Epilepsy

4. Recognized Establishments
4.1. United States
4.2. Europe
4.3. Japan

5. Epidemiology and Patient Population
5.1. Key Findings
5.2. 7MM Countries Total Diagnosed Incident Patient Population of Developmental and Epileptic Encephalopathies

6. Country Wise-Epidemiology of Developmental and Epileptic Encephalopathies
6.1. United States
6.1.1. Assumptions and Rationale
6.1.2. Developmental and Epileptic Encephalopathy Diagnosed Prevalence in the United States
6.1.3. Early Myoclonic Encephalopathy Diagnosed Prevalence in the United States
6.1.4. Epileptic Encephalopathy with continuous spike and wave during sleep Diagnosed Prevalence in the United States
6.1.5. Ohtahara Syndrome Diagnosed Prevalence in the United States
6.1.6. West Syndrome Diagnosed Prevalence in the United States
6.1.7. Landau-Kleffner Syndrome Diagnosed Prevalence in the United States
6.1.8. Lennox-Gastaut Syndrome Diagnosed Prevalence in the United States
6.1.9. Dravet Syndrome Diagnosed Prevalence in the United States
6.1.10. Doose Syndrome Diagnosed Prevalence in the United States
6.2. EU5 Countries
6.2.1. Assumptions and Rationale
6.3. Germany
6.3.1. Developmental and Epileptic Encephalopathy Diagnosed Prevalence in Germany
6.3.2. Early Myoclonic Encephalopathy Diagnosed Prevalence in Germany
6.3.3. Epileptic Encephalopathy with continuous spike and wave during sleep Diagnosed Prevalence in Germany
6.3.4. Ohtahara Syndrome Diagnosed Prevalence in Germany
6.3.5. West Syndrome Diagnosed Prevalence in Germany
6.3.6. Landau-Kleffner Syndrome Diagnosed Prevalence in Germany
6.3.7. Lennox-Gastaut Syndrome Diagnosed Prevalence in Germany
6.3.8. Dravet Syndrome Diagnosed Prevalence in Germany
6.3.9. Doose Syndrome Diagnosed Prevalence in Germany
6.4. France
6.4.1. Developmental and Epileptic Encephalopathy Diagnosed Prevalence in France
6.4.2. Early Myoclonic Encephalopathy Diagnosed Prevalence in France
6.4.3. Epileptic Encephalopathy with continuous spike and wave during sleep Diagnosed Prevalence in France
6.4.4. Ohtahara Syndrome Diagnosed Prevalence in France
6.4.5. West Syndrome Diagnosed Prevalence in France
6.4.6. Landau-Kleffner Syndrome Diagnosed Prevalence in France
6.4.7. Lennox-Gastaut Syndrome Diagnosed Prevalence in France
6.4.8. Dravet Syndrome Diagnosed Prevalence in France
6.4.9. Doose Syndrome Diagnosed Prevalence in France
6.5. Italy
6.5.1. Developmental and Epileptic Encephalopathy Diagnosed Prevalence in Italy
6.5.2. Early Myoclonic Encephalopathy Diagnosed Prevalence in Italy
6.5.3. Epileptic Encephalopathy with continuous spike and wave during sleep Diagnosed Prevalence in Italy
6.5.4. Ohtahara Syndrome Diagnosed Prevalence in Italy
6.5.5. West Syndrome Diagnosed Prevalence in Italy
6.5.6. West Syndrome Diagnosed Prevalence in Italy
6.5.7. Lennox-Gastaut Syndrome Diagnosed Prevalence in Italy
6.5.8. Dravet Syndrome Diagnosed Prevalence in Italy
6.5.9. Doose Syndrome Diagnosed Prevalence in Italy
6.6. Spain
6.6.1. Developmental and Epileptic Encephalopathy Diagnosed Prevalence in Spain
6.6.2. Early Myoclonic Encephalopathy Diagnosed Prevalence in Spain
6.6.3. Epileptic Encephalopathy with continuous spike and wave during sleep Diagnosed Prevalence in Spain
6.6.4. Ohtahara Syndrome Diagnosed Prevalence in Spain
6.6.5. West Syndrome Diagnosed Prevalence in Spain
6.6.6. Landau-Kleffner Syndrome Diagnosed Prevalence in Spain
6.6.7. Lennox-Gastaut Syndrome Diagnosed Prevalence in Spain
6.6.8. Dravet Syndrome Diagnosed Prevalence in Spain
6.6.9. Doose Syndrome Diagnosed Prevalence in Spain
6.7. United Kingdom
6.7.1. Developmental and Epileptic Encephalopathy Diagnosed Prevalence in the United Kingdom
6.7.2. Early Myoclonic Encephalopathy Diagnosed Prevalence in the United Kingdom
6.7.3. Epileptic Encephalopathy with continuous spike and wave during sleep Diagnosed Prevalence in the United Kingdom
6.7.4. Ohtahara Syndrome Diagnosed Prevalence in the United Kingdom
6.7.5. West Syndrome Diagnosed Prevalence in the United Kingdom
6.7.6. Landau-Kleffner Syndrome Diagnosed Prevalence in the United Kingdom
6.7.7. Lennox-Gastaut Syndrome Diagnosed Prevalence in the United Kingdom
6.7.8. Dravet Syndrome Diagnosed Prevalence in the United Kingdom
6.7.9. Doose Syndrome Diagnosed Prevalence in the United Kingdom
6.8. Japan
6.8.1. Assumptions and Rationale
6.8.2. Developmental and Epileptic Encephalopathy Diagnosed Prevalence in Japan
6.8.3. Early Myoclonic Encephalopathy Diagnosed Prevalence in Japan
6.8.4. Epileptic Encephalopathy with continuous spike and wave during sleep Diagnosed Prevalence in Japan
6.8.5. Ohtahara Syndrome Diagnosed Prevalence of in Japan
6.8.6. West Syndrome Diagnosed Prevalence of in Japan
6.8.7. Landau-Kleffner Syndrome Diagnosed Prevalence of in Japan
6.8.8. Lennox-Gastaut Syndrome Diagnosed Prevalence in Japan
6.8.9. Dravet Syndrome Diagnosed Prevalence in Japan
6.8.10. Doose Syndrome Diagnosed Prevalence in Japan

7. Treatment
7.1. Antiseizure medications
7.1.1. Clobazam (CLB)
7.1.2. Vigabatrin
7.1.3. Topiramate
7.1.4. Levetiracetam
7.1.5. Zonisamide
7.1.6. Phenobarbital
7.1.7. Cannabidiol
7.1.8. Stiripentol
7.1.9. Ethosuximide
7.1.10. Carbamazepine
7.1.11. Lemotrigien
7.2. Benzodiazapines (BZDs)
7.2.1. Clonazepam
7.2.2. Diazepam
7.2.3. Lorazepam
7.2.4. Nitrazepam
7.3. Other Class of Drugs
7.3.1. Phenobarbitone
7.3.2. Succinimides
7.3.3. Valproic acid
7.3.4. Rufinamide
7.3.5. Vigabatrin
7.3.6. Felbamate
7.4. Steroid therapy
7.4.1. Prednisolone
7.4.2. ACTH (Adrenocorticotropic Hormone)
7.5. Epilepsy surgery
7.5.1. Corpus callosotomy
7.6. Other Therapies
7.6.1. Vagus Nerve Stimulation
7.6.2. Ketogenic diet
7.7. Treatment Algorithm

8. Unmet Needs

9. Marketed Drugs
9.1. Lamictal: GlaxoSmithKline
9.1.1. Drug Description
9.1.2. Regulatory Milestones
9.1.3. Other Development Activities
9.1.4. Safety and Efficacy
9.1.5. Product Profile
9.2. Felbatol: Mylan Pharmaceuticals
9.2.1. Drug Description
9.2.2. Regulatory Milestones
9.2.3. Other Development Activities
9.2.4. Safety and Efficacy
9.2.5. Product Profile
9.3. Klonopin: Roche
9.3.1. Drug Description
9.3.2. Regulatory Milestones
9.3.3. Safety and Efficacy
9.3.4. Product Profile
9.4. Onfi: Lundbeck
9.4.1. Drug Description
9.4.2. Regulatory Milestones
9.4.3. Product Developmental Activities
9.4.4. Safety and Efficacy
9.4.5. Product Profile
9.5. Epidiolex: Greenwich Biosciences
9.5.1. Drug Description
9.5.2. Regulatory Milestones
9.5.3. Other Developmental Activities
9.5.4. Safety and Efficacy
9.5.5. Clinical Pipeline Activity
9.5.6. Product Profile
9.6. Banzel: Eisai
9.6.1. Drug Description
9.6.2. Regulatory Milestones
9.6.3. Other Developmental Activities
9.6.4. Advantages and Disadvantages
9.6.5. Safety and Efficacy
9.6.6. Product Profile
9.7. Topamax: Janssen Pharmaceuticals
9.7.1. Product Description
9.7.2. Regulatory Milestones
9.7.3. Other Developmental activities
9.7.4. Safety and Efficacy
9.7.5. Product Profile
9.8. Sabril: Lundbeck
9.8.1. Drug Production
9.8.2. Regulatory Milestones
9.8.3. Other Developmental Activities
9.8.4. Safety and Efficacy
9.8.5. Product Profile
9.9. Diacomit: Biocodex
9.9.1. Drug Description
9.9.2. Regulatory Milestones
9.9.3. Safety and Efficacy
9.9.4. Product Profile

10. Emerging Therapies
10.1. Key cross competition - Emerging Therapies
10.2. ZX008: Zogenix
10.2.1. Product Description
10.2.2. Other Developmental Activities
10.2.3. Regulatory Milestones
10.2.4. Clinical Development
10.2.5. Safety and Efficacy
10.2.6. Advantages and Disadvantages
10.2.7. Product Profile
10.3. Fycompa: Eisai Pharmaceuticals
10.3.1. Product Description
10.3.2. Other Developmental Activities
10.3.3. Clinical Development
10.3.4. Safety and Efficacy
10.3.5. Advantages and Disadvantages
10.3.6. Product Profile
10.4. Soticlestat (TAK-935/OV935): Takeda/Ovid
10.4.1. Product Description
10.4.2. Other Developmental Activities
10.4.3. Clinical Development
10.4.4. Safety and Efficacy
10.4.5. Product Profile
10.5. JBPOS0101: Bio-Pharm Solutions
10.5.1. Product Description
10.5.2. Other Developmental Activities
10.5.3. Clinical Development
10.5.4. Product Profile
10.6. Ataluren: PTC Therapeutics
10.6.1. Product Description
10.6.2. Other Developmental Activities
10.6.3. Clinical Development
10.6.4. Product Profile
10.7. ZYN002: Zynerba Pharma
10.7.1. Product Description
10.7.2. Other Developmental Activities
10.7.3. Clinical Development
10.7.4. Product Profile

11. What Experts Say?

12. Developmental and Epileptic Encephalopathies: 7 Major Market Analysis
12.1. Key Findings
12.2. Market Size of Developmental and Epileptic Encephalopathies in the 7MM Countries

13. The United States Market Outlook
13.1. United States
13.1.1. Total Market size of Developmental and Epileptic Encephalopathies (DEES)
13.1.2. Current Market Size by Therapies
13.1.3. Emerging Market Size by Therapies

14. EU-5 Countries: Market Outlook
14.1. Germany
14.1.1. Total Market size of Developmental and Epileptic Encephalopathies (DEES)
14.1.2. Current Market Size by Therapies
14.1.3. Emerging Market Size by Therapies
14.2. France
14.2.1. Total Market size of Developmental and Epileptic Encephalopathies (DEES)
14.2.2. Current Market Size by Therapies
14.2.3. Emerging Market Size by Therapies
14.3. Italy
14.3.1. Total Market size of Developmental and Epileptic Encephalopathies (DEES)
14.3.2. Current Market Size by Therapies
14.3.3. Emerging Market Size by Therapies
14.4. Spain
14.4.1. Total Market size of Developmental and Epileptic Encephalopathies (DEES)
14.4.2. Current Market Size by Therapies
14.4.3. Emerging Market Size by Therapies
14.5. United Kingdom
14.5.1. Total Market size of Developmental and Epileptic Encephalopathies (DEES)
14.5.2. Current Market Size by Therapies
14.5.3. Emerging Market Size by Therapies
14.6. Japan market Size
14.6.1. Total Market size of Developmental and Epileptic Encephalopathies (DEES)
14.6.2. Current Market Size by Therapies
14.6.3. Emerging Market Size by Therapies

15. Case Reports
15.1. Dravet syndrome: a new causative SCN1A mutation?
15.2. West syndrome in three patients with brain injury and a benign course
15.3. Novel biallelic SZT2 mutations in three cases of early-onset epileptic encephalopathy

16. Market Drivers

17. Market Barriers

18. Appendix
18.1. Report Methodology

19. Capabilities

20. Disclaimer

21. About the Publisher

List of Tables
Table 1: Main differences between atypical and typical absence seizures
Table 2: Nonepileptic and epileptic conditions to differentiate from Lennox-Gastaut syndrome
Table 3: Landau-Kleffner syndrome versus ECSWS
Table 4: miRNA in biofluids from patients with epilepsy.
Table 5: Summary of cytokines and their main role in epileptogenesis.
Table 6: Total Diagnosed Prevalent Population of Developmental and Epileptic Encephalopathies in the 7MM Countries
Table 7: Developmental and Epileptic Encephalopathy Diagnosed Prevalence in the United States (2017-2028)
Table 8: Early Myoclonic Encephalopathy Diagnosed Prevalence in the United States (2017-2028)
Table 9: Epileptic Encephalopathy with continuous spike and wave during sleep Diagnosed Prevalent Population of in the United States (2017-2028)
Table 10: Ohtahara Syndrome Diagnosed Prevalence in the United States (2017-2028)
Table 11: West Syndrome Diagnosed Prevalence in the United States (2017-2028)
Table 12: Landau-Kleffner Syndrome Diagnosed Prevalence in the United States (2017-2028)
Table 13: Lennox-Gastaut Syndrome Diagnosed Prevalence in the United States (2017-2028)
Table 14: Dravet Syndrome Diagnosed Prevalence in the United States (2017-2028)
Table 15: Doose Syndrome Diagnosed Prevalence in the United States (2017-2028)
Table 16: Developmental and Epileptic Encephalopathy Diagnosed Prevalence in Germany (2017-2028)
Table 17: Early Myoclonic Encephalopathy Diagnosed Prevalence in Germany (2017-2028)
Table 18: Epileptic Encephalopathy with continuous spike and wave Diagnosed Prevalent Population during sleep in Germany (2017-2028)
Table 19: Ohtahara Syndrome Diagnosed Prevalence in Germany (2017-2028)
Table 20: West Syndrome Diagnosed Prevalence in Germany (2017-2028)
Table 21: Landau-Kleffner Syndrome Diagnosed Prevalence in Germany (2017-2028)
Table 22: Lennox-Gastaut Syndrome Diagnosed Prevalence of in Germany (2017-2028)
Table 23: Dravet Syndrome Diagnosed Prevalence of in Germany (2017-2028)
Table 24: Doose Syndrome Diagnosed Prevalence in Germany (2017-2028)
Table 25: Developmental and Epileptic Encephalopathy Diagnosed Prevalence in France (2017-2028)
Table 26: Early Myoclonic Encephalopathy Diagnosed Prevalence in France (2017-2028)
Table 27: Epileptic Encephalopathy with continuous spike and wave during sleep Diagnosed Prevalent Population in France (2017-2028)
Table 28: Ohtahara Syndrome Diagnosed Prevalence in France (2017-2028)
Table 29: West Syndrome Diagnosed Prevalence in France (2017-2028)
Table 30: Landau-Kleffner Syndrome Diagnosed Prevalence in France (2017-2028)
Table 31: Lennox-Gastaut Syndrome Diagnosed Prevalence of in France (2017-2028)
Table 32: Dravet Syndrome Diagnosed Prevalence of in France (2017-2028)
Table 33: Doose Syndrome Diagnosed Prevalence in France (2017-2028)
Table 34: Developmental and Epileptic Encephalopathy Diagnosed Prevalence in Italy (2017-2028)
Table 35: Early Myoclonic Encephalopathy Diagnosed Prevalence in Italy (2017-2028)
Table 36: Epileptic Encephalopathy with continuous spike and wave during sleep Diagnosed Prevalent Population in Italy (2017-2028)
Table 37: Ohtahara Syndrome Diagnosed Prevalence in Italy (2017-2028)
Table 38: West Syndrome Diagnosed Prevalence in Italy (2017-2028)
Table 39: Landau-Kleffner Syndrome Diagnosed Prevalence in Italy (2017-2028)
Table 40: Lennox-Gastaut Syndrome Diagnosed Prevalence in Italy (2017-2028)
Table 41: Dravet Syndrome Diagnosed Prevalence in Italy (2017-2028)
Table 42: Doose Syndrome Diagnosed Prevalence in Italy (2017-2028)
Table 43: Developmental and Epileptic Encephalopathy Diagnosed Prevalence in Spain (2017-2028)
Table 44: Early Myoclonic Encephalopathy Diagnosed Prevalence in Spain (2017-2028)
Table 45: Epileptic Encephalopathy with continuous spike and wave during sleep Diagnosed Prevalent Population in Spain (2017-2028)
Table 46: Ohtahara Syndrome Diagnosed Prevalence in Spain (2017-2028)
Table 47: West Syndrome Diagnosed Prevalence in Spain (2017-2028)
Table 48: Landau-Kleffner Syndrome Diagnosed Prevalence in Spain (2017-2028)
Table 49: Lennox-Gastaut Syndrome Diagnosed Prevalence in Spain (2017-2028)
Table 50: Dravet Syndrome Diagnosed Prevalence in Spain (2017-2028)
Table 51: Doose Syndrome Diagnosed Prevalence in Spain (2017-2028)
Table 52: Developmental and Epileptic Encephalopathy Diagnosed Prevalence in the United Kingdom (2017-2028)
Table 53: Early Myoclonic Encephalopathy Diagnosed Prevalence in the United Kingdom (2017-2028)
Table 54: Epileptic Encephalopathy with continuous spike and wave during sleep Diagnosed Prevalent Population of in United Kingdom (2017-2028)
Table 55: Ohtahara Syndrome Diagnosed Prevalence in the United Kingdom (2017-2028)
Table 56: West Syndrome Diagnosed Prevalence in the United Kingdom (2017-2028)
Table 57: Landau-Kleffner Syndrome Diagnosed Prevalence in the United Kingdom (2017-2028)
Table 58: Lennox-Gastaut Syndrome Diagnosed Prevalence in the United Kingdom (2017-2028)
Table 59: Dravet Syndrome Diagnosed Prevalence in the United Kingdom (2017-2028)
Table 60: Doose Syndrome Diagnosed Prevalence in the United Kingdom (2017-2028)
Table 61: Developmental and Epileptic Encephalopathy Diagnosed Prevalence in Japan (2017-2028)
Table 62: Early Myoclonic Encephalopathy Diagnosed Prevalence in Japan (2017-2028)
Table 63: Epileptic Encephalopathy with continuous spike and wave during sleep Diagnosed Prevalent Population in Japan (2017-2028)
Table 64: Diagnosed Prevalence of Ohtahara Syndrome in Japan (2017-2028)
Table 65: West Syndrome Diagnosed Prevalence in Japan (2017-2028)
Table 66: Landau-Kleffner Syndrome Diagnosed Prevalence in Japan (2017-2028)
Table 67: Lennox-Gastaut Syndrome Diagnosed Prevalence in Japan (2017-2028)
Table 68: Dravet Syndrome Diagnosed Prevalence in Japan (2017-2028)
Table 69: Doose Syndrome Diagnosed Prevalence in Japan (2017-2028)
Table 70: Comparison of Emerging Drugs
Table 71: ZX008, Clinical Trial Description, 2019
Table 72: ZX008 Clinical Trial Description, 2019
Table 73: Perampanel, Clinical Trial Description, 2019
Table 74: TAK-935, Clinical Trial Description, 2019
Table 75: JBPOS0101, Clinical Trial Description, 2019
Table 76: Ataluren, Clinical Trial Description, 2019
Table 77: 7 Major Market Size of Developmental and Epileptic Encephalopathies in USD Million (2017-2028)
Table 78: United States Market Size of Developmental and Epileptic Encephalopathies (DEES), USD Million (2017-202
Table 79: Market size of Developmental and Epileptic Encephalopathies (DEES) by therapies in the US, in USD Million (2017-2028)
Table 80: Market size of Developmental and Epileptic Encephalopathies (DEES) by therapies in the US, in USD Million (2017-2028)
Table 81: Germany Market Size of Developmental and Epileptic Encephalopathies (DEES), USD Million (2017-2028)
Table 82: Market size of Developmental and Epileptic Encephalopathies (DEES) by therapies in Germany, in USD Million (2017-2028)
Table 83: Market size of Developmental and Epileptic Encephalopathies (DEES) by therapies in Germany, in USD Million (2017-2028)
Table 84: France Market Size of Developmental and Epileptic Encephalopathies (DEES), USD Million (2017-2028)
Table 85: Market size of Developmental and Epileptic Encephalopathies (DEES) by therapies in France, in USD Million (2017-2028)
Table 86: Market size of Developmental and Epileptic Encephalopathies (DEES) by therapies in France, in USD Million (2017-2028)
Table 87: Italy Market Size of Developmental and Epileptic Encephalopathies (DEES), USD Million (2017-2028)
Table 88: Market size of Developmental and Epileptic Encephalopathies (DEES) by therapies in Italy, in USD Million (2017-2028)
Table 89: Market size of Developmental and Epileptic Encephalopathies (DEES) by therapies in Italy, in USD Million (2017-2028)
Table 90: Spain Market Size of Developmental and Epileptic Encephalopathies (DEES), USD Million (2017-2028)
Table 91: Market size of Developmental and Epileptic Encephalopathies (DEES) by therapies in Spain, in USD Million (2017-2028)
Table 92: Market size of Developmental and Epileptic Encephalopathies (DEES) by therapies in Spain, in USD Million (2017-2028)
Table 93: United Kingdom Market Size of Developmental and Epileptic Encephalopathies (DEES), USD Million (2017-2028)
Table 94: Market size of Developmental and Epileptic Encephalopathies (DEES) by therapies in United Kingdom, (2017-2028)
Table 95: Market size of Developmental and Epileptic Encephalopathies (DEES) by therapies in United Kingdom, in USD (2017-2028)
Table 96: Japan Market Size of Developmental and Epileptic Encephalopathies (DEES), USD Million (2017-2028)
Table 97: Market size of Developmental and Epileptic Encephalopathies (DEES) by therapies in Japan, in USD Million (2017-2028)
Table 98: Market size of Developmental and Epileptic Encephalopathies (DEES) by therapies in Japan, in USD Million (2017-2028)

List of Figures
Figure 1: Neonatal Seizure and epilepsy Classification
Figure 2: The spectrum of SCN1A Disorders
Figure 3: Oxidative stress and hypoxia as the key players of epileptogenesis.
Figure 4: Potential mechanisms occurring during epileptogenesis and their correlations with one another.
Figure 5: Total Diagnosed Prevalent Patient Population of Developmental and Epileptic Encephalopathies in the 7MM Countries (2017-2028)
Figure 6: Developmental and Epileptic Encephalopathy Diagnosed Prevalence in the United States (2017-2028)
Figure 7: Early Myoclonic Encephalopathy Diagnosed Prevalence in the United States (2017-2028)
Figure 8: Epileptic Encephalopathy with continuous spike and wave during sleep Diagnosed Prevalent Population of in the United States (2017-2028)
Figure 9: Ohtahara Syndrome Diagnosed Prevalence in the United States (2017-2028)
Figure 10: West Syndrome Diagnosed Prevalence in the United States (2017-2028)
Figure 11: Landau-Kleffner Syndrome Diagnosed Prevalence in the United States (2017-2028)
Figure 12: Lennox-Gastaut Syndrome Diagnosed Prevalence in the United States (2017-2028)
Figure 13: Dravet Syndrome Diagnosed Prevalence in the United States (2017-2028)
Figure 14: Doose Syndrome Diagnosed Prevalence in the United States (2017-2028)
Figure 15: Developmental and Epileptic Encephalopathy Diagnosed Prevalence in Germany (2017-2028)
Figure 16: Early Myoclonic Encephalopathy Diagnosed Prevalence in Germany (2017-2028)
Figure 17: Epileptic Encephalopathy with continuous spike and wave Diagnosed Prevalent Population during sleep in Germany (2017-2028)
Figure 18: Ohtahara Syndrome Diagnosed Prevalence in Germany (2017-2028)
Figure 19: West Syndrome Diagnosed Prevalence in Germany (2017-2028)
Figure 20: Landau-Kleffner Syndrome Diagnosed Prevalence in Germany (2017-2028)
Figure 21: Lennox-Gastaut Syndrome Diagnosed Prevalence of in Germany (2017-2028)
Figure 22: Dravet Syndrome Diagnosed Prevalence of in Germany (2017-2028)
Figure 23: Doose Syndrome Diagnosed Prevalence in Germany (2017-2028)
Figure 24: Developmental and Epileptic Encephalopathy Diagnosed Prevalence in France (2017-2028)
Figure 25: Early Myoclonic Encephalopathy Diagnosed Prevalence in France (2017-2028)
Figure 26: Epileptic Encephalopathy with continuous spike and wave during sleep Diagnosed Prevalent Population in France (2017-2028)
Figure 27: Ohtahara Syndrome Diagnosed Prevalence in France (2017-2028)
Figure 28: West Syndrome Diagnosed Prevalence in France (2017-2028)
Figure 29: Landau-Kleffner Syndrome Diagnosed Prevalence in France (2017-2028)
Figure 30: Lennox-Gastaut Syndrome Diagnosed Prevalence of in France (2017-2028)
Figure 31: Dravet Syndrome Diagnosed Prevalence of in France (2017-2028)
Figure 32: Doose Syndrome Diagnosed Prevalence in France (2017-2028)
Figure 33: Developmental and Epileptic Encephalopathy Diagnosed Prevalence in Italy (2017-2028)
Figure 34: Early Myoclonic Encephalopathy Diagnosed Prevalence in Italy (2017-2028)
Figure 35: Epileptic Encephalopathy with continuous spike and wave during sleep Diagnosed Prevalent Population in Italy (2017-2028)
Figure 36: Ohtahara Syndrome Diagnosed Prevalence in Italy (2017-2028)
Figure 37: West Syndrome Diagnosed Prevalence in Italy (2017-2028)
Figure 38: Landau-Kleffner Syndrome Diagnosed Prevalence in Italy (2017-2028)
Figure 39: Lennox-Gastaut Syndrome Diagnosed Prevalence in Italy (2017-2028)
Figure 40: Dravet Syndrome Diagnosed Prevalence in Italy (2017-2028)
Figure 41: Doose Syndrome Diagnosed Prevalence in Italy (2017-2028)
Figure 42: Developmental and Epileptic Encephalopathy Diagnosed Prevalence in Spain (2017-2028)
Figure 43: Early Myoclonic Encephalopathy Diagnosed Prevalence in Spain (2017-2028)
Figure 44: Epileptic Encephalopathy with continuous spike and wave during sleep Diagnosed Prevalent Population in Spain (2017-2028)
Figure 45: Ohtahara Syndrome Diagnosed Prevalence in Spain (2017-2028)
Figure 46: West Syndrome Diagnosed Prevalence in Spain (2017-2028)
Figure 47: Landau-Kleffner Syndrome Diagnosed Prevalence in Spain (2017-2028)
Figure 48: Lennox-Gastaut Syndrome Diagnosed Prevalence in Spain (2017-2028)
Figure 49: Dravet Syndrome Diagnosed Prevalence in Spain (2017-2028)
Figure 50: Doose Syndrome Diagnosed Prevalence in Spain (2017-2028)
Figure 51: Developmental and Epileptic Encephalopathy Diagnosed Prevalence in the United Kingdom (2017-2028)
Figure 52: Early Myoclonic Encephalopathy Diagnosed Prevalence in the United Kingdom (2017-2028)
Figure 53: Epileptic Encephalopathy with continuous spike and wave during sleep Diagnosed Prevalent Population of in United Kingdom (2017-2028)
Figure 54: Ohtahara Syndrome Diagnosed Prevalence in the United Kingdom (2017-2028)
Figure 55: West Syndrome Diagnosed Prevalence in the United Kingdom (2017-2028)
Figure 56: Landau-Kleffner Syndrome Diagnosed Prevalence in the United Kingdom (2017-2028)
Figure 57: Lennox-Gastaut Syndrome Diagnosed Prevalence in the United Kingdom (2017-2028)
Figure 58: Dravet Syndrome Diagnosed Prevalence in the United Kingdom (2017-2028)
Figure 59: Doose Syndrome Diagnosed Prevalence in the United Kingdom (2017-2028)
Figure 60: Developmental and Epileptic Encephalopathy Diagnosed Prevalence in Japan (2017-2028)
Figure 61: Early Myoclonic Encephalopathy Diagnosed Prevalence in Japan (2017-2028)
Figure 62: Epileptic Encephalopathy with continuous spike and wave during sleep Diagnosed Prevalent Population in Japan (2017-2028)
Figure 63: Diagnosed Prevalence of Ohtahara Syndrome in Japan (2017-2028)
Figure 64: West Syndrome Diagnosed Prevalence in Japan (2017-2028)
Figure 65: Landau-Kleffner Syndrome Diagnosed Prevalence in Japan (2017-2028)
Figure 66: Lennox-Gastaut Syndrome Diagnosed Prevalence in Japan (2017-2028)
Figure 67: Dravet Syndrome Diagnosed Prevalence in Japan (2017-2028)
Figure 68: Doose Syndrome Diagnosed Prevalence in Japan (2017-2028)
Figure 69: Unmet Needs of Differential Epileptic Encephalopathy (DEES)
Figure 70: 7 Major Market Size of Developmental and Epileptic Encephalopathies in USD Million (2017-2028)
Figure 71: Market Size of Developmental and Epileptic Encephalopathies (DEES) in the United States, USD Millions (2017-2028)
Figure 72: Market size of Developmental and Epileptic Encephalopathies (DEES) by therapies in the US, in USD Million (2017-2028)
Figure 73: Market size of Developmental and Epileptic Encephalopathies (DEES) by therapies in the US, in USD Million (2017-2028)
Figure 74: Market Size of Developmental and Epileptic Encephalopathies (DEES) in Germany, USD Millions (2017-2028)
Figure 75: Market size of Developmental and Epileptic Encephalopathies (DEES) by therapies in Germany, in USD Million (2017-2028)
Figure 76: Market size of Developmental and Epileptic Encephalopathies (DEES) by therapies in Germany, in USD Million (2017-2028)
Figure 77: Market Size of Developmental and Epileptic Encephalopathies (DEES) in France, USD Millions (2017-2028)
Figure 78: Market size of Developmental and Epileptic Encephalopathies (DEES) by therapies in France, in USD Million (2017-2028)
Figure 79: Market size of Developmental and Epileptic Encephalopathies (DEES) by therapies in France, in USD Million (2017-2028)
Figure 80: Market Size of Developmental and Epileptic Encephalopathies (DEES) in Italy, USD Millions (2017-2028)
Figure 81: Market size of Developmental and Epileptic Encephalopathies (DEES) by therapies in Italy, in USD Million (2017-2028)
Figure 82: Market size of Developmental and Epileptic Encephalopathies (DEES) by therapies in Italy, in USD Million (2017-2028)
Figure 83: Market Size of Developmental and Epileptic Encephalopathies (DEES) in Spain, USD Millions (2017-2028)
Figure 84: Market size of Developmental and Epileptic Encephalopathies (DEES) by therapies in Spain, in USD Million (2017-2028)
Figure 85: Market size of Developmental and Epileptic Encephalopathies (DEES) by therapies in Spain, in USD Million (2017-2028)
Figure 86: Market Size of Developmental and Epileptic Encephalopathies (DEES) in the United Kingdom, USD Millions (2017-2028)
Figure 87: Market size of Developmental and Epileptic Encephalopathies (DEES) by therapies in the United Kingdom, in USD Million (2017-2028)
Figure 88: Market size of Developmental and Epileptic Encephalopathies (DEES) by therapies in the United Kingdom, in USD Million (2017-2028)
Figure 89: Market Size of Developmental and Epileptic Encephalopathies (DEES) in Japan, USD Millions (2017-2028)
Figure 90: Market size of Developmental and Epileptic Encephalopathies (DEES) by therapies in Japan, in USD Million (2017-2028)
Figure 91: Market size of Developmental and Epileptic Encephalopathies (DEES) by therapies in Japan, in USD Million (2017-2028)
Figure 92: Market Drivers
Figure 93: Market Barriers

Note: Product cover images may vary from those shown
  • Biocodex
  • Bio-Pharm Solutions
  • Eisai Pharmaceuticals
  • GlaxoSmithKline
  • Greenwich Biosciences
  • Janssen Pharmaceuticals
  • Lundbeck
  • Mylan Pharmaceuticals
  • PTC Therapeutics
  • Roche
  • Takeda/Ovid
  • Zogenix
  • Zynerba Pharma
Note: Product cover images may vary from those shown
Adroll
adroll